LUMINEX CORPORATION TO HOST INVESTOR EVENT AT ASSOCIATION FOR MOLECULAR PATHOLOGY ANNUAL MEETING UNVEILING NEW SAMPLE-TO-ANSWER SYSTEM
AUSTIN, Texas, Oct. 29, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that management will host an investor event in Phoenix, Arizona at the Association for Molecular Pathology Annual Meeting on Wednesday, November 13, 2013 beginning at 5:30 pm Mountain time.
Patrick J. Balthrop, president and chief executive officer, and other members of the executive management team will provide insight into the company's long-term strategic plans, including a live demonstration of the Company's revolutionary sample-to-answer System, Project ARIES.
Advanced registration is required and attendance will be limited to those registered. To register, please contact Matthew Norman, Government and Investor Relations Manager. Dinner will be served following the event.
The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. Please go to the website at least 15 minutes prior to the event to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the presentation will be archived for six months on the website using the 'replay' link.
About Luminex Corporation
Luminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. The Company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP open-architecture, multi-analyte platform and MultiCode® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. The Company is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com/.
Matthew Norman, 512.219.8020
Government and Investor Relations Manager
Harriss Currie, 512.219.8020
Sr. Vice President and CFO
SOURCE Luminex Corporation